Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acoramidis versus placebo in symptomatic transthyretin amyloid cardiomyopathy
MOH_2019-08-13_007149Phase 3Completed
- Sponsor
- Eidos Therapeutics
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) comparing acoramidis with placebo (2 arms). Started May 2019; status: completed.
02
Drugs
acoramidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on MOH_2019-08-13_007149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-13_007149.